Salute e Benessere
Photocure ASA: Results for the third quarter of 2024
Photocure reported total group revenues of NOK 120.2 million in the third quarter of 2024 ( NOK 107.5 million ), and EBITDA* of NOK 5.0 million ( NOK 3.3 million ), driven by revenue growth in North America and Europe . Hexvix/Cysview revenues ended at NOK 120.1 million in the quarter (Q3 2023: NOK 107.3 million ). The EBIT was NOK -2.2 million ( NOK -3.9 million ) and the cash balance at the end of the period was NOK 291.1 million .
At the end of the third quarter of 2024, the installed base of rigid BLC systems in the U.S. was 387, up 13% since Q3 2023. This includes 18 mobile towers owned by ForTec Medical. Photocure estimates that 25 flexible BLC towers remain in the U.S. market. Photocure also entered into a strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation flexible blue light cystoscope based on Richard Wolf's system blue technology with the goal to reintroduce and grow the use of BLC with Cysview/Hexvix in the surveillance setting.
Schneider adds.
Photocure believes that the benefits of Blue Light Cystoscopy with Hexvix/Cysview offering superior detection and management of bladder cancer will continue to be adopted and become the standard of care. Photocure reiterates its 2024 guidance and continues to expect consolidated product revenue growth of 6% to 9% in constant currency, positive EBITDA excluding business development expenses, and new and upgraded Saphira installations in the U.S. in the range of 55 to 70 towers.
Schneider concludes.
Please find the full financial report and presentation enclosed.
EBITDA* and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the third quarter 2024 financial report on page 23.
The quarterly report and presentation will be published at
08:00 CET and will be publicly available at
Dan Schneider, CEO and Erik Dahl , CFO, will host a live webcast at
14:00 CET .
The presentation will be held in English and questions can be submitted throughout the event. The streaming event is available through
The presentation is scheduled to conclude at 14:45 CET .
Dan Schneider
President and CEO
Photocure ASA
Email: Erik Dahl
Chief Financial Officer
Email: David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: Media and IR enquiries:
Geir Bjørlo
Corporate Communications ( Norway )
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.hexvix.com , www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Tolv Hillestad, Group Controller, Photocure ASA, on 13 November 2024 at 08:00 CET .
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: